Polycyclo Ring System Having The Oxazine Ring As One Of The Cyclos Patents (Class 544/89)
  • Patent number: 10202401
    Abstract: The present invention is directed to a process for making Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2 and R3 are defined above herein. The present invention is also directed to compounds that may be useful as synthetic intermediates in the process of the invention.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: February 12, 2019
    Assignees: MSD R&D CN CO., LTD, MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME LIMITED
    Inventors: Hongming Li, Jingjun Yin, Kevin M. Belyk, Kevin R. Campos, Qinghao Chen, Alan M. Hyde, Tetsuji Itoh, Artis Klapars, Matthew Thomas Tudge, Edward Cleator, Aaron M. Dumas, Louis-Charles Campeau, Yonggang Chen, Ji Qi, Wensong Xiao
  • Patent number: 10131674
    Abstract: The present invention is directed to a process for preparing Substituted Indole Compounds of Formula (I): wherein R1, R2, R3 and R4 are as defined herein. These indole compounds are useful as synthetic intermediates for making inhibitors of HCV NS5A.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: November 20, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel A. DiRocco, Ian Davies, Feng Peng, Mark McLaughlin, Louis-Charles Campeau, Yingju Xu
  • Patent number: 9725464
    Abstract: The present invention is directed to a process for preparing Tetracyclic Heterocycle Compounds of formula (I): which are useful as HCV NS5A inhibitors. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: August 8, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian Mangion, Cheng-yi Chen, Ingyu Jeon, Yonggang Chen, Hongmei Li, Hoa N. Nguyen, Peter E. Maligres, Artis Klapars, Ilia Zavialov, Nobuyoshi Yasuda
  • Patent number: 9555038
    Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: January 31, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wensheng Yu, Ling Tong, Joseph A. Kozlowski, Oleg Selyutin, Lei Chen, Jae-Hun Kim, Deyou Sha, Razia Rizvi, Bandarpalle Shankar
  • Patent number: 9416128
    Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein n, R1, R2, R2?, R3, R4, R5, R6 and R7 are as described herein, and to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: August 16, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Rao Kalla, Thao Perry, Jeff Zablocki
  • Patent number: 9206196
    Abstract: Novel benzoxazino quinoline derivatives of Formula (I) and benzoxazino isoquinoline derivatives of Formula (II) are provided: Also provided is a transition-metal-free multicomponent reaction of arynes, N-heterocycles, and carbonyl compounds leading to the diastereoselective synthesis of benzoxazino quinoline derivatives of Formula (I) and benzoxazino isoquinoline derivatives of formula (II) in good yields proceeding via 1,4-zwitterionic intermediates. The compounds possess anti-malarial activity.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: December 8, 2015
    Assignee: Council of Scientific & Industrial Research
    Inventors: Akkattu Thankappan Biju, Anup Bhunia, Dhanasekaran Shanmugam
  • Patent number: 9139596
    Abstract: The invention provides prodrugs of DNA-reactive analogs of duocarmycin and CC-1065 anticancer agents, wherein a cyclic prodrug form, such as carbamate, thionocarbamate, or carbamimidate, can be hydrolyzed by the patient in vivo to yield a respective bioactive agent comprising a DNA-alkylating moiety and a binding/targeting moiety. The DNA-reactive moiety is a ?-spirocyclohexenone fused to a heterocyclyl group which can be produced by endogenous hydrolysis of a cyclic carbamate prodrug of the invention. The cyclic carbamate prodrug produces no residual byproduct during activation in vivo. Methods of synthesis and biological methods and data are also provided.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: September 22, 2015
    Assignee: The Scripps Research Institute
    Inventor: Dale L. Boger
  • Patent number: 9062011
    Abstract: The present invention relates to a benzoxazine intermediate and a preparation method thereof. The structural formula of the benzoxazine intermediate is shown by formula (1), R1 in formula represents O, C?O, S, SO2, alicyclic hydrocarbon with 3 to 30 carbon atoms and derivatives thereof, aliphatic hydrocarbon with 1 to 20 carbon atoms and derivatives thereof, or unsaturated aliphatic hydrocarbon with 2 to 20 carbon atoms and derivatives thereof; R2 is alicyclic hydrocarbon with 3 to 20 carbon atoms and derivatives thereof, aliphatic hydrocarbon with 1 to 20 carbon atoms and derivatives thereof, or unsaturated aliphatic hydrocarbon with 2 to 20 carbon atoms and derivatives thereof. The benzoxazine intermediate of the present invention contains a naphthalene ring structure segment, has desirable heat resistance performance and flame retarding performance, and can be widely applied in composite materials.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: June 23, 2015
    Assignee: Shengyi Technology Co., Ltd.
    Inventors: Shiguo Su, Yueshan He
  • Patent number: 9040526
    Abstract: The present application describes modulators of MCP-1 or CCR-2 of formula or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, n, W, X, R1 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: May 26, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ian K. Mangion, Percy H. Carter, Jingwu Duan, Andrew J. Tebben
  • Publication number: 20150005287
    Abstract: The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile-associated diarrhea.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 1, 2015
    Inventors: Mamuti ABUDUSAIMI, Fangguo YE, Jiangqin SUN, Hisashi MIYAMOTO, Jay-Fei CHENG, Daisuke OKA
  • Publication number: 20140364429
    Abstract: Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: AB PHARMA LTD.
    Inventor: Zheng-Yun James ZHAN
  • Patent number: 8871759
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: October 28, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig A. Coburn, Steven W. Ludmerer, Kun Liu, Hao Wu, Richard Soll, Bin Zhong, Jian Zhu
  • Publication number: 20140296229
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4, A1 and A2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 2, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Harald ENGELHARDT, Davide GIANNI, Andreas MANTOULIDIS, Christian SMETHURST
  • Patent number: 8801976
    Abstract: Photochromic dyes are disclosed. A photochromic dye can include a first photo-reactive group and a second photo-reactive group. A first photochromic reaction can be induced in the first photo-reactive group of the photochromic dye by radiation having a first wavelength, and a second photochromic reaction can be induced in the second photo-reactive group of the photochromic dye by radiation having a second wavelength.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: August 12, 2014
    Assignee: Korea University Research and Business Foundation
    Inventor: Dong Hoon Choi
  • Publication number: 20140213571
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: August 20, 2012
    Publication date: July 31, 2014
    Inventors: Nigel J. Liverton, Casey Cameron McComas, Joerg Habermann, Uwe Koch, Frank Narjes, Peng Li, Xuanjia Peng, Richard Soll, Hao Wu, Anandan Palani, Shuwen He, Xing Dai, Hong Liu, Zhong Lai, Clare London, Dong Xiao, Nicolas Zorn, Ravi Nargund
  • Patent number: 8784684
    Abstract: A compound which has a benzoxazinone ring and an aromatic ring that directly bonds to the benzoxazinone ring, and has a mesogenic core substituted by a substituent having a polymerizable functional group is excellent in terms of durability, colorless, and exhibits a high ?n while having an azomethine bond.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: July 22, 2014
    Assignee: FUJIFILM Corporation
    Inventors: Satoshi Shimamura, Mitsuyoshi Ichihashi
  • Patent number: 8772283
    Abstract: The present invention provides an imidazooxazine compound represented by Formula (I) or a salt thereof, wherein A, B, C, and D are as defined in the specification.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: July 8, 2014
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Masayuki Nakamura, Kenji Niiyama, Kaori Kamijo, Mitsuru Ohkubo, Toshiyasu Shimomura
  • Publication number: 20140179675
    Abstract: The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile-associated diarrhea.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Mamuti ABUDUSAIMI, Fangguo YE, Jiangqin SUN, Hisashi MIYAMOTO, Jay-Fei CHENG, Daisuke OKA
  • Patent number: 8507148
    Abstract: A benzoxazine-based monomer includes a halogen atom-containing functional group and a nitrogen-containing heterocyclic group. A polymer formed from the benzoxazine-based monomer may be used in an electrode for a fuel cell and electrolyte membrane for a fuel cell.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: August 13, 2013
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Seongwoo Choi, Jungock Park
  • Publication number: 20120295899
    Abstract: The present application describes modulators of MCP-1 or CCR-2 of formula or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, n, W, X, R1 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
    Type: Application
    Filed: February 8, 2011
    Publication date: November 22, 2012
    Inventors: Ian K. Mangion, Percy H. Carter, Jingwu Duan, Andrew J. Tebben
  • Publication number: 20120283220
    Abstract: The present invention provides compounds of Formula (I-IV): compositions containing the same, and methods of use thereof such as for the treatment of cancer.
    Type: Application
    Filed: September 22, 2010
    Publication date: November 8, 2012
    Inventors: Kuo-Hsiung Lee, Xiaoming Yang, Qian Shi, Kenneth F. Bastow, Che-Ming Teng, Tse-Ming Hong, Pan-Chyr Yang, Shuenn-Chen Yang
  • Patent number: 8304537
    Abstract: Heterocyclic compounds incorporating a [1,3]oxazine ring may be used to make chromogenic materials. These molecules switch from a colorless state to a colored form upon addition of either acid or base. In both instances, the [1,3]oxazine ring opens in response to the pH change forming an indolium cation, after the addition of acid, or a phenolate anion, after the addition of base. Alternatively, the switch may occur in response to a change in electrical current or potential or a change in temperature. Chromophores absorb in the visible region of the electromagnetic spectrum. Hence, their formation translates into the appearance of color. These processes are fully reversible and the original colorless state can be regenerated by switching the pH back to neutral. Thus, these halochromic compounds can be used to develop displays, filters, indicators, lenses, sensors, switches, or windows able to switch their color in response to pH changes.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: November 6, 2012
    Assignee: The University of Miami
    Inventors: Massimiliano Tomasulo, Francisco M. Raymo
  • Patent number: 8298453
    Abstract: Photochromic dyes are disclosed. A photochromic dye can include a first photo-reactive group and a second photo-reactive group. A first photochromic reaction can be induced in the first photo-reactive group of the photochromic dye by radiation having a first wavelength, and a second photochromic reaction can be induced in the second photo-reactive group of the photochromic dye by radiation having a second wavelength.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: October 30, 2012
    Assignee: Korea University Research and Business Foundation
    Inventor: Dong Hoon Choi
  • Patent number: 8287775
    Abstract: Photochromic dyes are disclosed. A photochromic dye can include a first photo-reactive group and a second photo-reactive group. A first photochromic reaction can be induced in the first photo-reactive group of the photochromic dye by radiation having a first intensity, and a second photochromic reaction can be induced in the second photo-reactive group of the photochromic dye by radiation having a second intensity. The second intensity may be greater than the first intensity.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: October 16, 2012
    Assignee: Korea University Research and Business Foundation
    Inventor: Dong Hoon Choi
  • Patent number: 8252209
    Abstract: We have designed a molecular switch based on the photoinduced opening and thermal closing of a [1,3]oxazine ring. A substituted [1,3]oxazine compound described as having a general (i.e., unsubstituted) structure with fused indoline and benzooxazine fragments such that they share a common bond in the [1,3]oxazine compound: (i) the bond connecting positions 1 and 2 of the indoline fragment and (ii) the bond connecting positions 2 and 3 of the benzooxazine fragment. Irradiation by light of suitable wavelength and intensity of this photochromic compound induces cleavage of a [C—O] bond of the [1,3]oxazine ring to form a phenolate chromophore. The photogenerated (e.g., colored) isomer may revert thermally to the starting (e.g., colorless) oxazine. Alternatively, the switch may be between isomers of the compound that absorb at different wavelengths. Reversible coloration of silica or polymeric materials and switching optical signals may involve many cycles of interconversion between different colored states.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: August 28, 2012
    Assignee: The University of Miami
    Inventors: Francisco M. Raymo, Massimiliano Tomasulo
  • Patent number: 8198436
    Abstract: A chromogenic oxazine compound for the colorimetric detection of cyanide was designed. Indeed, the [1,3]oxazine ring of our compound opens to form a phenolate chromophore in response to cyanide. The heterocyclic com-pound may be comprised of fused benzooxazine and indoline rings: wherein R1 is an alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl), a substituted alkyl, a cycloalkyl (e.g., cyclopentyl, cyclohexyl), a substituted cycloalkyl, an aryl (e.g., phenyl), or a substituted aryl and R2 is a chromophore (e.g., nitroso, nitro, azo dyes). This quantitative chromogenic transformation permits the detection of micromolar concentrations of cyanide in water. Furthermore, our chromogenic oxazine is insensitive to the presence of large concentrations of fluoride, chloride, bromide or iodide anions, which are generally the principal interferents in the colorimetric detection of cyanide.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: June 12, 2012
    Assignee: The University of Miami
    Inventors: Francisco M. Raymo, Massimiliano Tomasulo
  • Patent number: 8187766
    Abstract: A benzoxazine-based monomer includes a halogen atom-containing functional group and a nitrogen-containing heterocyclic group. A polymer formed from the benzoxazine-based monomer may be used in an electrode for a fuel cell and electrolyte membrane for a fuel cell.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: May 29, 2012
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Seongwoo Choi, Jungock Park
  • Patent number: 8173644
    Abstract: This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, an in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to a compound useful for treatment of such conditions, and methods of using this compound for such treatment.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: May 8, 2012
    Assignee: Les Laboratoires Servier
    Inventors: Alexis Cordi, Gary Rogers, Rudolf Mueller
  • Publication number: 20120094989
    Abstract: The present invention relates to compounds having 5-hydroxytryptamine receptor modulating activity, in particular compounds having an acidic moiety held distant from the 5-HT pharmacophore by a rigid linker group, to compositions containing such compounds and methods of treatment using them. Such compounds have an increased affinity for the 5-HT receptor and a reduced hERG effect. Certain compounds of the invention further exhibit an angiotensin II receptor modulating activity. Claimed are compounds of formula (I): HT-L-A. HT is a 5-HT receptor modulating moiety containing a basic nitrogen atom; A is an acid moiety; L is a linker moiety.
    Type: Application
    Filed: April 1, 2010
    Publication date: April 19, 2012
    Applicant: SERODUS AS
    Inventors: Jo Klaveness, Bjame Brudeli, Finn Olav Levy, Lise Roman Moltzau, Trygve Gulbrandsen
  • Publication number: 20120070409
    Abstract: The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
    Type: Application
    Filed: February 3, 2011
    Publication date: March 22, 2012
    Applicant: Japan Tobacco Inc.
    Inventors: Takahiro Oka, Kazutaka Ikegashira, Shintaro Hirashima, Hiroshi Yamanaka, Satoru Noji, Yasushi Niwa, Yoko Matsumoto, Toshihiro Sato, Izuru Ando, Yukihiro Nomura
  • Publication number: 20120040930
    Abstract: The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.
    Type: Application
    Filed: January 13, 2006
    Publication date: February 16, 2012
    Inventors: Catherine Guillou, Jean-Yves Lallemand, Thibault Sauvaítre, Jordi Molgo, Denyse Herlem, Daniel Guenard, Françoise Khuong-Huu
  • Patent number: 8088788
    Abstract: [1,2]Imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and imidazo[4,5-c]pyridines) substituted with a fused ring containing an oxygen and/or nitrogen atom attached at the 1- and/or 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: January 3, 2012
    Assignee: 3M Innovative Properties Company
    Inventors: Tushar A. Kshirsagar, Karl J. Manske, Larry R. Krepski, Joan T. Moseman, George W. Griesgraber, Sarah Johannessen Slania, Scott E. Langer, Philip D. Heppner
  • Publication number: 20110313153
    Abstract: The invention relates generally to the treatment of diseases of the respiratory system such as asthma and chronic obstructive pulmonary disease. More particularly, the present invention relates to methods of treating and preventing asthmatic airway inflammation. The treatment involves the administration of a 5-HT4 receptor antagonist to the subject in need thereof; more in particular the administration of aroylated 4-aminomethylpiperidine derivatives as defined herein. Other aspects of the invention are directed to compositions for treating or preventing respiratory disorders, including pharmaceutical compositions.
    Type: Application
    Filed: January 28, 2010
    Publication date: December 22, 2011
    Inventors: Ann Meulemans, Leen Thielemans, Joris De Maeyer, Jan Schuurkes
  • Patent number: 7998951
    Abstract: The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: August 16, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, John F. Kadow
  • Publication number: 20110095243
    Abstract: We have designed a molecular switch based on the photoinduced opening and thermal closing of a [1,3]oxazine ring. A substituted [1,3]oxazine compound described as having a general (i.e., unsubstituted) structure with fused indoline and benzooxazine fragments such that they share a common bond in the [1,3]oxazine compound: (i) the bond connecting positions 1 and 2 of the indoline fragment and (ii) the bond connecting positions 2 and 3 of the benzooxazine fragment. Irradiation by light of suitable wavelength and intensity of this photochromic compound induces cleavage of a [C—O] bond of the [1,3]oxazine ring to form a phenolate chromophore. The photogenerated (e.g., colored) isomer may revert thermally to the starting (e.g., colorless) oxazine. Alternatively, the switch may be between isomers of the compound that absorb at different wavelengths. Reversible coloration of silica or polymeric materials and switching optical signals may involve many cycles of interconversion between different colored states.
    Type: Application
    Filed: August 6, 2010
    Publication date: April 28, 2011
    Inventors: Francisco M. Raymo, Massimiliano Tomasulo
  • Patent number: 7834010
    Abstract: The invention relates to modulators of peripheral 5-HT receptors, particularly 5-HT4 receptors, said modulators essentially selective for peripheral 5-HT receptors over receptors of the central nervous system. The invention allows for the treatment, amongst others, of gastrointestinal disorders, lower urinary tract disorders, and cardiovascular disorders without side effects related to CNS activity.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: November 16, 2010
    Assignee: Serodus AS
    Inventors: Jo Klaveness, Finn Olav Levy, Bjarne Brudeli
  • Publication number: 20100249403
    Abstract: Heterocyclic compounds incorporating a [1,3]oxazine ring may be used to make chromogenic materials. These molecules switch from a colorless state to a colored form upon addition of either acid or base. In both instances, the [1,3]oxazine ring opens in response to the pH change forming an indolium cation, after the addition of acid, or a phenolate anion, after the addition of base. Alternatively, the switch may occur in response to a change in electrical current or potential or a change in temperature. Chromophores absorb in the visible region of the electromagnetic spectrum. Hence, their formation translates into the appearance of color. These processes are fully reversible and the original colorless state can be regenerated by switching the pH back to neutral. Thus, these halochromic compounds can be used to develop displays, filters, indicators, lenses, sensors, switches, or windows able to switch their color in response to pH changes.
    Type: Application
    Filed: October 17, 2008
    Publication date: September 30, 2010
    Inventors: Massimiliano Tomasulo, Francisco M. Raymo
  • Patent number: 7799913
    Abstract: This invention related to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed In a variety of dementias, and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson?s disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to compounds useful for treatment of such conditions and methods of using these compounds for such treatment.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: September 21, 2010
    Assignee: Cortex Pharmaceuticals, Inc.
    Inventors: Gary A. Rogers, Matthew Allan, Clayton Harris, Jianjie Huang, Christopher M. Marrs, Rudolf Mueller, Stanislaw Rachwal
  • Patent number: 7795251
    Abstract: The present invention relates 3,4-dihydro-benzo[e][1,3]oxazin-2-ones which are substituted at the nitrogen atom by unsubstituted or substituted (C1-8)alkyl, (C3-8)cycloalkyl, (C3-8)cycloalkyl(C1-4)alkyl, (C6-18)aryl or (C6-18)aryl(C1-4)alkyl and their use as pharmaceuticals.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: September 14, 2010
    Assignee: Novartis AG
    Inventors: Andreas Billich, Hubert Gstach, Philipp Lehr
  • Publication number: 20090258429
    Abstract: A chromogenic oxazine compound for the colorimetric detection of cyanide was designed. Indeed, the [1,3]oxazine ring of our compound opens to form a phenolate chromophore in response to cyanide. The heterocyclic com-pound may be comprised of fused benzooxazine and indoline rings: wherein R1 is an alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl), a substituted alkyl, a cycloalkyl (e.g., cyclopentyl, cyclohexyl), a substituted cycloalkyl, an aryl (e.g., phenyl), or a substituted aryl and R2 is a chromophore (e.g., nitroso, nitro, azo dyes). This quantitative chromogenic transformation permits the detection of micromolar concentrations of cyanide in water. Furthermore, our chromogenic oxazine is insensitive to the presence of large concentrations of fluoride, chloride, bromide or iodide anions, which are generally the principal interferents in the colorimetric detection of cyanide.
    Type: Application
    Filed: September 1, 2006
    Publication date: October 15, 2009
    Inventors: Francisco M. Raymo, Massimiliano Tomasulo
  • Publication number: 20090163485
    Abstract: The present invention relates to compounds of formula wherein Ar, Het, R1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.
    Type: Application
    Filed: December 15, 2008
    Publication date: June 25, 2009
    Inventors: Henner Knust, Matthias Nettekoven, Emmanuel Pinard, Olivier Roche, Mark Rogers-Evans
  • Patent number: 7527654
    Abstract: The present invention relates to a process for dyeing keratin fibers, in particular human keratin fibers such as the hair, using a dye composition comprising at least one dye of styryl or imine type in the presence of a revealing composition comprising at least one optionally substituted (hetero) aromatic compound of weak acid type. The present invention makes it possible in particular to obtain a chromatic and fast coloration of keratin fibers, which is visible even on dark hair without prior lightening. The invention also makes it possible to obtain a coloration which, under certain conditions, does not stain.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: May 5, 2009
    Assignee: L'Oreal S.A.
    Inventor: Grégory Plos
  • Publication number: 20090029979
    Abstract: This invention relates to compounds which bind to serotonin receptors inside or outside the central nervous system, in particular compounds which bind to the 5-HT2 or 5-HT7 receptors, their preparation and use, compositions containing them, and methods of treatment using them.
    Type: Application
    Filed: July 7, 2006
    Publication date: January 29, 2009
    Applicant: BIO-MEDISINSK INNOVASJON AS
    Inventors: Jo Klaveness, Bjarne Brudeli, Finn Olav Levy
  • Publication number: 20090029978
    Abstract: The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR2, R1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups and R2 is hydrogen or a group as defined for R1.
    Type: Application
    Filed: July 24, 2008
    Publication date: January 29, 2009
    Applicant: Alizyme Therapeutics Limited
    Inventors: Harold Francis HODSON, Christopher Robert DUNK, Richard Michael John PALMER, Dale Robert MITCHELL, Veronique BIRAULT, Russell George HUNT
  • Publication number: 20080312218
    Abstract: In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimers disease.
    Type: Application
    Filed: September 21, 2006
    Publication date: December 18, 2008
    Inventors: Duane A. Burnett, Wen-Lian Wu
  • Patent number: 7435733
    Abstract: This invention relates to compounds that bind to mineralocorticoid receptors and/or modulate activity of mineralocorticoid receptors, and to methods for making and using such compounds. Some embodiments relate to compounds of Formula I: or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein R1-R10 are as defined herein.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: October 14, 2008
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Robert I. Higuchi, Lin Zhi, Donald S. Karanewsky
  • Patent number: 7196108
    Abstract: The invention relates to certain bicyclic heterocycles havng the structure shown below which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, and atherosclerosis.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: March 27, 2007
    Assignees: Incyte San Diego Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul Giachino, Karine Jakubowicz-Jaillardon, Jianhua Guo, Richard M. Fine, Lyle W. Spruce, James W. Zapf
  • Patent number: 7160936
    Abstract: An ultraviolet radiation absorbent for thermoplastic polymer materials such as polyethylene terephthalate or polycarbonate contains cyclic imino ester compound of a specified structure in an amount of over 99.5 weight % and less than 100 weight % and having an acid value in the range of 1×10?3–1 and/or a chlorine ion content in the range of 1×10?1–1×103 ppm.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: January 9, 2007
    Assignees: Takemoto Yushi Kabushiki Kaisha, Teijin Dupont Films Japan Limited
    Inventors: Tatsuhiko Osaki, Tetsuo Ichihashi
  • Patent number: 7112674
    Abstract: The invention relates to an organic electroluminescent device which contains 2,5-diaminoterephthalic acid derivatives of formula 1a as emitter substances in one or several emitter layers in a pure or doped manner. The ring A is a triple unsaturated benzene ring wherein R4? and R8? are zero or ring A is a double unsaturated ring respectively provided with a double bond in the 1,2 position and 4,5 position, and wherein R10 is a nitrile radical —CN or a radical C(?X1)—X2R1, R11 is a nitrile radical —CN or a radical —C(?X3)—X4R5, X1 and X3 are oxygen, sulfur or imino, X2 and X4 are oxygen, sulfur or optionally substituted amino, R1–R8, R4? and R8? are H, C1–20-alkyl, aryl, heteroaryl, R4 and R8 can be halogen, nitro, cyanogen or amino, R2–R4, R6–R8, R4? and R8? can be trifluoromethyl or pentafluorophenyl, and wherein certain radicals can form a saturated or unsaturated ring.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: September 26, 2006
    Assignee: Sensient Imaging Technologies GmbH
    Inventors: Andreas Richter, Jens Schoenewerk, Gerhard Diener
  • Patent number: 7053138
    Abstract: Compounds of formula (I) or (II), wherein R1 is C1–C18alkyl; C5–C12cycloalkyl that is unsubstituted or substituted by one or more C1–C6alkyl groups or C1–C6alkoxy groups; C5–C22aryl that is unsubstituted or substituted by one or more C1–C6alkyl groups or C1–C6alkoxy groups; or C7–C30aralkyl that is unsubstituted or substituted by one or more C1–C6alkyl groups or C1–C6alkoxy groups, and the radicals R2 to R13 are each independently of the others hydrogen; —NO2; dialkylamino; alkylthio; alkylsulfonyl; halogen; C1–C18alkyl; C1–C18alkoxy; C1–C18alkoxyalkyl; C5–C12cycloalkyl that is unsubstituted or substituted by one or more C1–C6alkyl groups or C1–C6alkoxy groups; C5–C22aryl that is unsubstituted or substituted by one or more C1–C6alkyl groups or C1–C6alkoxy groups; or C7–C30aralkyl that is unsubstituted or substituted by one or more C1–C6alkyl groups or C1–C6alkoxy groups, are suitable as flame-proofing agents for thermoplastic or thermosetting polymers
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: May 30, 2006
    Assignee: Huntsman Advanced Materials Americas Inc.
    Inventors: Franck Magendie, Ulrich Weidmann